IDEX Corporation announced today the appointment of Mark A. Beck to the company’s Board of Directors, effective January 1, 2018.
“We are thrilled to welcome Mark to our Board of Directors,” said IDEX Chairman and Chief Executive Officer Andrew Silvernail. “His experience as a chief executive officer of a public company with significant international operations and his track record of innovation and successfully integrating acquired businesses will be a tremendous asset to IDEX. Mark is a values-based, results-oriented leader, making him a great fit with our Board and management.”
Beck has served as President and Chief Executive Officer of JELD-WEN Holding, Inc. (“JELD-WEN”), one of the world’s largest door and window manufacturers, since November 2015, and was appointed as a Director of JELD-WEN in May 2016. He joined JELD-WEN from Danaher Corporation, where he served as Executive Vice President, leading Danaher’s Water Quality and Dental platforms, beginning in April 2014. Previously, he spent 18 years with Corning Incorporated in a series of management positions with increasing responsibility, culminating in his appointment as Executive Vice President overseeing Corning’s Environmental Technologies and Life Science units in July 2012. He also served on the board of directors of Dow-Corning Corporation from 2010 to 2014. Beck holds a B.A. in Business Management from Pacific University and an M.B.A. from Harvard Business School.
Monday, the French pharma giant officially moved into its new global home base in Paris, dubbed La Maison Sanofi. The 9,000-square-meter (about 96,875-square-foot) facility comprises two historic buildings and will host around 500 employees, the company explained in a release.
On the first day of the new year, former Sandoz chief Richard Francis will take the reins from Schultz, who is hanging up his CEO hat to retire on Dec. 31, Teva said Monday. The news comes a little more than two weeks after Teva publicly said it was looking for Schultz’s replacement.
General Electric Co. set the terms for the spinoff of its healthcare division, putting an initial value of roughly $31 billion on the soon-to-be-public company. The Boston conglomerate plans to split into three separate public companies by early 2024. Following the healthcare spinoff, it plans to separate its aerospace business from its power and renewable-energy units.